Compare MDWD & APYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDWD | APYX |
|---|---|---|
| Founded | 2000 | 1982 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 181.1M | 196.4M |
| IPO Year | 2013 | 1995 |
| Metric | MDWD | APYX |
|---|---|---|
| Price | $13.53 | $3.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $36.00 | $6.50 |
| AVG Volume (30 Days) | 59.8K | ★ 91.9K |
| Earning Date | 05-20-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $48.92 | $11.93 |
| Revenue Next Year | $35.04 | $11.01 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.54 | $1.70 |
| 52 Week High | $20.30 | $5.08 |
| Indicator | MDWD | APYX |
|---|---|---|
| Relative Strength Index (RSI) | 36.09 | 27.19 |
| Support Level | N/A | $2.76 |
| Resistance Level | $15.08 | $4.31 |
| Average True Range (ATR) | 0.48 | 0.32 |
| MACD | -0.05 | -0.12 |
| Stochastic Oscillator | 4.81 | 7.21 |
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Surgical Aesthetics and Original Equipment Manufacturing (OEM). Its Surgical Aesthetics segment derives the majority of its revenue.